Genmab — Maj 2019
-
Winkel fra CC om RTOR og Maia: It's up to the gods at the FDA right now, but I think the process is going well, and there is no reason to be concerned at all. It's an experimental program. It's a pilot program. So the time lines are not fixed, but we expect it very, very shortly.
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company AnnouncementCopenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
3,000 shares at DKK 40.41,
5,000 s -
Proceeds to the company are approximately DKK 1.61 million. The increase corresponds to approx. 0.02% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2019. The new shares will be listed on Nasdaq Copenhagen after registration with th
-
God morgen
-
God morgen.
-
-
RTOR er forsinket 37 dage, pga nedlukningen.
-
Jeg mener godkendelsen derfor kommer 24. Marts omkring midnat
-
- Maj (ikke marts)
)
️
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind